Literature DB >> 33754038

Single-cell transcriptome analysis of the heterogeneous effects of differential expression of tumor PD-L1 on responding TCR-T cells.

Renpeng Ding1,2, Shang Liu1,2, Shanshan Wang1,2, Huanyi Chen1, Fei Wang1,2, Qumiao Xu1,3, Linnan Zhu1,4, Xuan Dong1,3, Ying Gu1,5, Xiuqing Zhang1,3, Cheng-Chi Chao1, Qianqian Gao1,3,4.   

Abstract

Rationale: TCR-T cell therapy plays a critical role in the treatment of malignant cancers. However, it is unclear how TCR-T cells are affected by PD-L1 molecule in the tumor environment. We performed an in-depth evaluation on how differential expressions of tumor PD-L1 can affect the functionality of T cells.
Methods: We used MART-1-specific TCR-T cells (TCR-TMART-1), stimulated with MART-127-35 peptide-loaded MEL-526 tumor cells, expressing different proportions of PD-L1, to perform cellular assays and high-throughput single-cell RNA sequencing.
Results: Different clusters of activated or cytotoxic TCR-TMART-1 responded divergently when stimulated with tumor cells expressing different percentages of PD-L1 expression. Compared to control T cells, TCR-TMART-1 were more sensitive to exhaustion, and secreted not only pro-inflammatory cytokines but also anti-inflammatory cytokines with increasing proportions of PD-L1+ tumor cells. The gene profiles of chemokines were modified by increased expression of tumor PD-L1, which concurrently downregulated pro-inflammatory and anti-inflammatory transcription factors. Furthermore, increased expression of tumor PD-L1 showed distinct effects on different inhibitory checkpoint molecules (ICMs). In addition, there was a limited correlation between the enrichment of cell death signaling in tumor cells and T cells and increased tumor PD-L1 expression.
Conclusion: Overall, though the effector functionality of TCR-T cells was suppressed by increased expression percentages of tumor PD-L1 in vitro, scRNA-seq profiles revealed that both the anti-inflammatory and pro-inflammatory responses were triggered by a higher expression of tumor PD-L1. This suggests that the sole blockade of tumor PD-L1 might inhibit not only the anti-inflammatory response but also the pro-inflammatory response in the complicated tumor microenvironment. Thus, the outcome of PD-L1 intervention may depend on the final balance among the highly dynamic and heterogeneous immune regulatory circuits. © The author(s).

Entities:  

Keywords:  PD-L1; TCR-T; differential expression; melanoma; single-cell RNA sequencing

Mesh:

Substances:

Year:  2021        PMID: 33754038      PMCID: PMC7978322          DOI: 10.7150/thno.55075

Source DB:  PubMed          Journal:  Theranostics        ISSN: 1838-7640            Impact factor:   11.556


  54 in total

1.  Pembrolizumab for the treatment of non-small-cell lung cancer.

Authors:  Edward B Garon; Naiyer A Rizvi; Rina Hui; Natasha Leighl; Ani S Balmanoukian; Joseph Paul Eder; Amita Patnaik; Charu Aggarwal; Matthew Gubens; Leora Horn; Enric Carcereny; Myung-Ju Ahn; Enriqueta Felip; Jong-Seok Lee; Matthew D Hellmann; Omid Hamid; Jonathan W Goldman; Jean-Charles Soria; Marisa Dolled-Filhart; Ruth Z Rutledge; Jin Zhang; Jared K Lunceford; Reshma Rangwala; Gregory M Lubiniecki; Charlotte Roach; Kenneth Emancipator; Leena Gandhi
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

2.  Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity.

Authors:  Masaki Mandai; Junzo Hamanishi; Kaoru Abiko; Noriomi Matsumura; Tsukasa Baba; Ikuo Konishi
Journal:  Clin Cancer Res       Date:  2016-03-25       Impact factor: 12.531

3.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

4.  Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.

Authors:  R Houston Thompson; Michael D Gillett; John C Cheville; Christine M Lohse; Haidong Dong; W Scott Webster; Kent G Krejci; John R Lobo; Shomik Sengupta; Lieping Chen; Horst Zincke; Michael L Blute; Scott E Strome; Bradley C Leibovich; Eugene D Kwon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-29       Impact factor: 11.205

5.  PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer.

Authors:  Brian Diskin; Salma Adam; Marcelo F Cassini; Gustavo Sanchez; Miguel Liria; Berk Aykut; Chandan Buttar; Eric Li; Belen Sundberg; Ruben D Salas; Ruonan Chen; Junjie Wang; Mirhee Kim; Mohammad Saad Farooq; Susanna Nguy; Carmine Fedele; Kwan Ho Tang; Ting Chen; Wei Wang; Mautin Hundeyin; Juan A Kochen Rossi; Emma Kurz; Muhammad Israr Ul Haq; Jason Karlen; Emma Kruger; Zennur Sekendiz; Dongling Wu; Sorin A A Shadaloey; Gillian Baptiste; Gregor Werba; Shanmugapriya Selvaraj; Cynthia Loomis; Kwok-Kin Wong; Joshua Leinwand; George Miller
Journal:  Nat Immunol       Date:  2020-03-09       Impact factor: 25.606

6.  Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.

Authors:  Haidong Dong; Scott E Strome; Diva R Salomao; Hideto Tamura; Fumiya Hirano; Dallas B Flies; Patrick C Roche; Jun Lu; Gefeng Zhu; Koji Tamada; Vanda A Lennon; Esteban Celis; Lieping Chen
Journal:  Nat Med       Date:  2002-06-24       Impact factor: 53.440

7.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

8.  A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.

Authors:  Livnat Jerby-Arnon; Parin Shah; Michael S Cuoco; Christopher Rodman; Mei-Ju Su; Johannes C Melms; Rachel Leeson; Abhay Kanodia; Shaolin Mei; Jia-Ren Lin; Shu Wang; Bokang Rabasha; David Liu; Gao Zhang; Claire Margolais; Orr Ashenberg; Patrick A Ott; Elizabeth I Buchbinder; Rizwan Haq; F Stephen Hodi; Genevieve M Boland; Ryan J Sullivan; Dennie T Frederick; Benchun Miao; Tabea Moll; Keith T Flaherty; Meenhard Herlyn; Russell W Jenkins; Rohit Thummalapalli; Monika S Kowalczyk; Israel Cañadas; Bastian Schilling; Adam N R Cartwright; Adrienne M Luoma; Shruti Malu; Patrick Hwu; Chantale Bernatchez; Marie-Andrée Forget; David A Barbie; Alex K Shalek; Itay Tirosh; Peter K Sorger; Kai Wucherpfennig; Eliezer M Van Allen; Dirk Schadendorf; Bruce E Johnson; Asaf Rotem; Orit Rozenblatt-Rosen; Levi A Garraway; Charles H Yoon; Benjamin Izar; Aviv Regev
Journal:  Cell       Date:  2018-11-01       Impact factor: 41.582

Review 9.  Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.

Authors:  Ming Yi; Dechao Jiao; Hanxiao Xu; Qian Liu; Weiheng Zhao; Xinwei Han; Kongming Wu
Journal:  Mol Cancer       Date:  2018-08-23       Impact factor: 27.401

10.  Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules.

Authors:  Michael T Bethune; Xiao-Hua Li; Jiaji Yu; Jami McLaughlin; Donghui Cheng; Colleen Mathis; Blanca Homet Moreno; Katherine Woods; Ashley J Knights; Angel Garcia-Diaz; Stephanie Wong; Siwen Hu-Lieskovan; Cristina Puig-Saus; Jonathan Cebon; Antoni Ribas; Lili Yang; Owen N Witte; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-22       Impact factor: 11.205

View more
  1 in total

Review 1.  Heterogeneity of the tumor immune microenvironment and its clinical relevance.

Authors:  Qingzhu Jia; Aoyun Wang; Yixiao Yuan; Bo Zhu; Haixia Long
Journal:  Exp Hematol Oncol       Date:  2022-04-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.